Cargando…

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases

The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is a direct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yi, Jiang, Hua, Chen, Yun, Wang, Xiaqiong, Yang, Yanqing, Tao, Jinhui, Deng, Xianming, Liang, Gaolin, Zhang, Huafeng, Jiang, Wei, Zhou, Rongbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887903/ https://www.ncbi.nlm.nih.gov/pubmed/29531021 http://dx.doi.org/10.15252/emmm.201708689

Ejemplares similares

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
por: He, Hongbin, et al.
Publicado: (2018)

CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation
por: Tang, Tiantian, et al.
Publicado: (2017)

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
por: Jiang, Hua, et al.
Publicado: (2017)

Perfluorodecanoic acid stimulates NLRP3 inflammasome assembly in gastric cells
por: Zhou, Xiangyu, et al.
Publicado: (2017)

An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups
por: Lin, Hualong, et al.
Publicado: (2022)

Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis
por: Chen, Suwen, et al.
Publicado: (2020)

Pachydermodactyly Treated with Tranilast in a Young Girl
por: Higuchi, Chikahisa, et al.
Publicado: (2014)

Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019)

Inhibition of the Inflammasome Activity of NLRP3 Attenuates HDM-Induced Allergic Asthma
por: Ma, Ming, et al.
Publicado: (2021)

Uricosuric targets of tranilast
por: Mandal, Asim K., et al.
Publicado: (2017)

Tranilast Directly Targets NLRP3 to Protect Melanocytes From Keratinocyte-Derived IL-1β Under Oxidative Stress
por: Zhuang, Tongtian, et al.
Publicado: (2020)

NLRP3 Inhibitor Tranilast Attenuates Gestational Diabetes Mellitus in a Genetic Mouse Model
por: Cao, Jing, et al.
Publicado: (2022)

Inhibition of the NLRP3 Inflammasome Activation by Manoalide Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis
por: Li, Cong, et al.
Publicado: (2022)

Apilimod activates the NLRP3 inflammasome through lysosome-mediated mitochondrial damage
por: Hou, Yingting, et al.
Publicado: (2023)

BAFF-driven NLRP3 inflammasome activation in B cells
por: Lim, Ken-Hong, et al.
Publicado: (2020)

The role of NLRP3 inflammasome in digestive system malignancy
por: Sun, Cen-Cen, et al.
Publicado: (2022)

Editorial: Novel perspectives on the NLRP3 inflammasome
por: Liang, Ying, et al.
Publicado: (2023)

A case of granuloma faciale successfully treated with oral prednisone, tranilast and thalidomide
por: Yuan, Chunyu, et al.
Publicado: (2018)

Sex-Related Overactivation of NLRP3 Inflammasome Increases Lethality of the Male COVID-19 Patients
por: Zhang, Hongliang, et al.
Publicado: (2021)

Protection against Ovariectomy-Induced Bone Loss by Tranilast
por: Phan, Tien Van, et al.
Publicado: (2014)

The NLRP3 inflammasome in viral infection (Review)
por: Zheng, Qiaoli, et al.
Publicado: (2023)

Tranilast enhances the effect of anticancer agents in osteosarcoma
por: Nakashima, Takayuki, et al.
Publicado: (2019)

The NLRP6 inflammasome
por: Zheng, Danping, et al.
Publicado: (2020)

Regulation of NLRP3 Inflammasome by Phosphorylation
por: Song, Nan, et al.
Publicado: (2018)

ASC deglutathionylation is a checkpoint for NLRP3 inflammasome activation
por: Li, Shuhang, et al.
Publicado: (2021)

Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis
por: Chung, I-Che, et al.
Publicado: (2016)

Role of NLRP3 inflammasome in systemic sclerosis
por: Lin, Cong, et al.
Publicado: (2022)

Granulation after stenting for tuberculous bronchial stenosis treated with tranilast: A case report
por: Ohashi, Takuya, et al.
Publicado: (2022)

Homotypic CARD-CARD interaction is critical for the activation of NLRP1 inflammasome
por: Xu, Zhihao, et al.
Publicado: (2021)

NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation
por: Wang, Zhilei, et al.
Publicado: (2022)

Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
por: Xu, Haowen, et al.
Publicado: (2023)

Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
por: Ding, Nan, et al.
Publicado: (2020)

NLRP3 Inflammasome and Inflammatory Diseases
por: Wang, Zheng, et al.
Publicado: (2020)

Procyanidins alleviates morphine tolerance by inhibiting activation of NLRP3 inflammasome in microglia
por: Cai, Yang, et al.
Publicado: (2016)

A Pilot Study of Tranilast for Cardiomyopathy of Muscular Dystrophy
por: Matsumura, Tsuyoshi, et al.
Publicado: (2017)

NLRP3 inflammasome in endothelial dysfunction
por: Bai, Baochen, et al.
Publicado: (2020)

Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast
por: Noakes, Rowland
Publicado: (2018)

Calycosin Alleviates Doxorubicin-Induced Cardiotoxicity and Pyroptosis by Inhibiting NLRP3 Inflammasome Activation
por: Zhang, Lei, et al.
Publicado: (2022)

Inhibiting the NLRP3 Inflammasome
por: El-Sharkawy, Lina Y., et al.
Publicado: (2020)

The Roles of Endoplasmic Reticulum in NLRP3 Inflammasome Activation
por: Zhou, Yang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9bquhov69e06r1o6fsq6phqbfn